DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis



Status:Recruiting
Conditions:Psoriasis
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:12 - 16
Updated:9/2/2018
Start Date:August 19, 2015
End Date:December 2018
Contact:Carmela Fritz
Email:cfritz@promiuspharma.com
Phone:6093759929

Use our guide to learn which trials are right for you!

A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%

To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the
hypothalamic-pituitary-adrenal (HPA) axis.

To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the
hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days or when
applied twice daily for 29 days, in adolescent subjects with moderate to severe plaque
psoriasis under maximal use conditions.

Inclusion Criteria:

1. Subjects must weigh at least 55 pounds

2. Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque
psoriasis.

3. Subjects with psoriasis involving ≥ 10% BSA, not including the face, scalp, groin,
axillae and other intertriginous areas..

4. Subjects must have moderate to severe plaque psoriasis at the Baseline Visit.

5. Subjects whose results from the screening ACTH stimulation test are considered normal
(cortisol level >18 ug/dL at 30 minutes post stimulation) and show no other signs of
abnormal HPA axis function or adrenal response.

Exclusion Criteria:

1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic,
exfoliative or pustular psoriasis.

2. History of organ transplant requiring immunosuppression, HIV, or other
immunocompromised state.

3. Have received treatment for any type of cancer within 5 years of the Baseline Visit.

4. Use within 60 days prior to the Baseline Visit of: 1) immunosuppressive drugs (e.g.,
tacrolimus, pimecrolimus), 2) systemic antipsoriatic treatment (e.g., methotrexate,
cyclosporine, hydroxyurea), or 3) biologic treatment for psoriasis (e.g., infliximab,
adalimumab, etanercept, ustekinumab, secukinumab, or alefacept).

5. Use within 30 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs
(salicylic acid, anthralin, coal tar, calcipotriene), 2) PUVA therapy, 3) systemic
anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine),
or 4) UVB therapy.

6. Use within 30 days prior to the Screening Visit of any product containing
corticosteroids. Inhaled, intraocular, intranasal, etc. steroids are not allowed.

7. Subjects who have an abnormal sleep schedule or work overnight.

8. Subjects with a known history of acute adrenal crisis, Addison's disease or decreased
adrenal output, low pituitary function or pituitary tumors.

9. Subjects who have a history of an adverse reaction to cosyntropin injection or similar
test reagents.
We found this trial at
8
sites
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Arlington, TX
Click here to add this to my saved trials
?
mi
from
Encino, CA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Irvine, CA
Click here to add this to my saved trials
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials